Advanced Development of Informatics Technologies for Cancer Research and Management (U24)

The summary for the Advanced Development of Informatics Technologies for Cancer Research and Management (U24) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Advanced Development of Informatics Technologies for Cancer Research and Management (U24): The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum, including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Initiative, this FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research.In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process should be included. Potential applicants who are interested in early-stage development or informatics resource sustainment should consult companion FOAs listed above.

Federal Grant Title:	Advanced Development of Informatics Technologies for Cancer Research and Management (U24)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAR-15-331
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.396
CFDA Descriptions:	Cancer Biology Research
Current Application Deadline:	Jun 14, 2018
Original Application Deadline:	Jun 14, 2018
Posted Date:	Aug 18, 2015
Creation Date:	Aug 18, 2015
Archive Date:	Jul 15, 2018
Total Program Funding:
Maximum Federal Grant Award:	$600,000
Minimum Federal Grant Award:	none
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: County governments
Public housing authorities/Indian housing authorities
City or township governments
Private institutions of higher education
Others (see text field entitled "Additional Information on Eligibility" for clarification)
For profit organizations other than small businesses
Independent school districts
Special district governments
Native American tribal governments (Federally recognized)
Small businesses
Public and State controlled institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
State governments
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/PAR-15-331.html
Grant Announcement Contact: NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants: • New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Opt...; • Mechanisms of Fusion-Driven Oncogenesis in Childhood Cancers (U01 Clinical Trial Not Allow...; • Advancing Cancer Control Equity Research Through Transformative Solutions (U19 Clinical Tr...; • Advancing Cancer Control Equity Research through Transformative Solutions Coordination Cen...; • Liver Cancer Collaborative Projects with the Liver Cirrhosis Network (U01 Clinical Trial O...; • Mouse Models of Human Cancers Consortium; • Integrative Cancer Biology Programs; • Memory T Lymphocytes in Cancer Immunology (R21)
More Grants from the National Institutes of Health: • Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed); • Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed); • Small Research Grant Program for the Next Generation of Researchers in Low- and Middle-Inc...; • Consortium for Neuroscience AD/ADRD in Low- and Middle-Income Countries (U01 Clinical Tri...; • Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed...